Lates News

German biotechnology company BioNTech is reducing the production scale of its cell therapy in the United States, as the candidate drug under its CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) program did not meet expected plans in early cancer trials. By the end of this summer, BioNTech's cell therapy factory in Gaithersburg, Maryland will lay off 63 employees, mainly affecting the cell therapy technology operations team at the site.